These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

151 related items for PubMed ID: 19147669

  • 1. Nail-patella syndrome, infantile nephrotic syndrome: complete remission with antiproteinuric treatment.
    Proesmans W, Van Dyck M, Devriendt K.
    Nephrol Dial Transplant; 2009 Apr; 24(4):1335-8. PubMed ID: 19147669
    [Abstract] [Full Text] [Related]

  • 2. Nail-patella syndrome, infantile nephrotic syndrome: complete remission with antiproteinuric treatment.
    Soliman N.
    Nephrol Dial Transplant; 2009 Sep; 24(9):2951; author reply 2951-2. PubMed ID: 19541663
    [No Abstract] [Full Text] [Related]

  • 3. Randomized, controlled study of the effects of losartan versus enalapril in small doses on proteinuria and tubular injury in primary glomerulonephritis.
    Tylicki L, Renke M, Rutkowski P, Rutkowski B, Lysiak-Szydłowska W.
    Med Sci Monit; 2005 Apr; 11(4):PI31-7. PubMed ID: 15795705
    [Abstract] [Full Text] [Related]

  • 4. Efficacy of enalapril in the treatment of steroid resistant idiopathic nephrotic syndrome.
    Prasher PK, Varma PP, Baliga KV.
    J Assoc Physicians India; 1999 Feb; 47(2):180-2. PubMed ID: 10999084
    [Abstract] [Full Text] [Related]

  • 5. Glomerular abundance of nephrin and podocin in experimental nephrotic syndrome: different effects of antiproteinuric therapies.
    Nakhoul F, Ramadan R, Khankin E, Yaccob A, Kositch Z, Lewin M, Assady S, Abassi Z.
    Am J Physiol Renal Physiol; 2005 Oct; 289(4):F880-90. PubMed ID: 15942045
    [Abstract] [Full Text] [Related]

  • 6. Enalapril: antiproteinuric effect in children with nephrotic syndrome.
    Lama G, Luongo I, Piscitelli A, Salsano ME.
    Clin Nephrol; 2000 Jun; 53(6):432-6. PubMed ID: 10879662
    [Abstract] [Full Text] [Related]

  • 7. Spontaneous remission of post-transplant recurrent focal and segmental glomerulosclerosis.
    Saeed B, Mazloum H, Askar M.
    Saudi J Kidney Dis Transpl; 2011 Nov; 22(6):1219-22. PubMed ID: 22089787
    [Abstract] [Full Text] [Related]

  • 8. Combined renin angiotensin blockade in childhood steroid-resistant nephrotic syndrome.
    Supavekin S, Surapaitoolkorn W, Tancharoen W, Pattaragarn A, Sumboonnanonda A.
    Pediatr Int; 2012 Dec; 54(6):793-7. PubMed ID: 22621380
    [Abstract] [Full Text] [Related]

  • 9. Losartan and enalapril are comparable in reducing proteinuria in children.
    Webb NJ, Shahinfar S, Wells TG, Massaad R, Gleim GW, Santoro EP, Sisk CM, Lam C.
    Kidney Int; 2012 Oct; 82(7):819-26. PubMed ID: 22739977
    [Abstract] [Full Text] [Related]

  • 10. Difficult-to-treat nephrotic syndrome: management and outcome.
    Sumboonnanonda A, Chongchate N, Suntornpoch V, Pattaragarn A, Supavekin S.
    J Med Assoc Thai; 2005 Nov; 88 Suppl 8():S142-8. PubMed ID: 16856434
    [Abstract] [Full Text] [Related]

  • 11. Influence of losartan and enalapril on urinary excretion of 8-isoprostane in experimental nephrotic syndrome.
    Tesar V, Zima T, Jirsa M, Crkovská J, Stípek S, Vernerová Z, Seráková M.
    Med Sci Monit; 2002 Feb; 8(2):BR69-74. PubMed ID: 11859270
    [Abstract] [Full Text] [Related]

  • 12. [Clinical state of a patient with nephrotic proteinuria successfully treated with combined therapy with angiotensin II receptor antagonists and angiotensin II converting enzyme inhibitors and pentoxifylline].
    Renke M, Rutkowski P, Tylicki L, Zietkiewicz M, Larczyński W, Rutkowski B.
    Przegl Lek; 2008 Feb; 65(6):312-4. PubMed ID: 18853664
    [Abstract] [Full Text] [Related]

  • 13. [Kidney involvement in hereditary osteo-onychodysplasia].
    Kozlovskaia NL, Tareeva IE, Popova VV, Miroshnichenko NG, Stavrovskaia EV.
    Ter Arkh; 1997 Feb; 69(6):37-9. PubMed ID: 9297271
    [Abstract] [Full Text] [Related]

  • 14. Additive antiproteinuric effect of enalapril and losartan in children with hemolytic uremic syndrome.
    Caletti MG, Balestracci A, Missoni M, Vezzani C.
    Pediatr Nephrol; 2013 May; 28(5):745-50. PubMed ID: 23250713
    [Abstract] [Full Text] [Related]

  • 15. Effectiveness of dietary protein augmentation associated with angiotensin-converting enzyme inhibition in the management of the nephrotic syndrome.
    Garini G, Mazzi A, Allegri L, Buzio C, Borghetti A.
    Miner Electrolyte Metab; 1996 May; 22(1-3):123-7. PubMed ID: 8676802
    [Abstract] [Full Text] [Related]

  • 16. Eplerenone potentiates the antiproteinuric effects of enalapril in experimental nephrotic syndrome.
    Nakhoul F, Khankin E, Yaccob A, Kawachi H, Karram T, Awaad H, Nakhoul N, Hoffman A, Abassi Z.
    Am J Physiol Renal Physiol; 2008 Mar; 294(3):F628-37. PubMed ID: 18094029
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of tacrolimus versus cyclosporine in children with steroid-resistant nephrotic syndrome: a randomized controlled trial.
    Choudhry S, Bagga A, Hari P, Sharma S, Kalaivani M, Dinda A.
    Am J Kidney Dis; 2009 May; 53(5):760-9. PubMed ID: 19268410
    [Abstract] [Full Text] [Related]

  • 18. Adequate clinical control of congenital nephrotic syndrome by enalapril.
    Guez S, Giani M, Melzi ML, Antignac C, Assael BM.
    Pediatr Nephrol; 1998 Feb; 12(2):130-2. PubMed ID: 9543371
    [Abstract] [Full Text] [Related]

  • 19. Primary prevention using losartan in type 1 diabetic patients significantly reduces retinopathy.
    Cardiovasc J Afr; 2009 Feb; 20(4):265. PubMed ID: 19701543
    [No Abstract] [Full Text] [Related]

  • 20. Losartan and enalapril are comparable in reducing proteinuria in children with Alport syndrome.
    Webb NJ, Shahinfar S, Wells TG, Massaad R, Gleim GW, McCrary Sisk C, Lam C.
    Pediatr Nephrol; 2013 May; 28(5):737-43. PubMed ID: 23207876
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.